Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hyttel

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
European Journal of Pharmacology|December 24, 1982
Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activityJ Arnt, A V Christensen, J Hyttel, et al.
European Journal of Pharmacology|June 15, 1984
Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomersJ Arnt, K P Bøgesø, J Hyttel, et al.
Journal of Medicinal Chemistry|March 1, 1990
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor modelT Liljefors, K P Bøgesø, J Hyttel, et al.
Journal of Medicinal Chemistry|October 27, 1995
Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activityK P Bøgesø, J Arnt, K Frederiksen, et al.
Journal of Medicinal Chemistry|December 1, 1988
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activityK P Bøgesø, J Arnt, V Boeck, et al.
Psychopharmacology|January 1, 1983
Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomersJ Arnt, K P Bøgesø, A V Christensen, et al.
Acta Pharmacologica Et Toxicologica|October 1, 1977
The pharmacology of a new potent, long acting neuroleptic, piflutixolI M Nielsen, V Boeck, A V Christensen, et al.
Clinical Neuropharmacology|January 1, 1992
Pharmacological profile of the atypical neuroleptic sertindoleJ Hyttel, J Arnt, B Costall, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
European Journal of Pharmacology|December 24, 1982
Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activityJ Arnt, A V Christensen, J Hyttel, et al.
European Journal of Pharmacology|June 15, 1984
Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomersJ Arnt, K P Bøgesø, J Hyttel, et al.
Journal of Medicinal Chemistry|March 1, 1990
Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor modelT Liljefors, K P Bøgesø, J Hyttel, et al.
Journal of Medicinal Chemistry|October 27, 1995
Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activityK P Bøgesø, J Arnt, K Frederiksen, et al.
Journal of Medicinal Chemistry|December 1, 1988
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activityK P Bøgesø, J Arnt, V Boeck, et al.
Psychopharmacology|January 1, 1983
Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomersJ Arnt, K P Bøgesø, A V Christensen, et al.
Acta Pharmacologica Et Toxicologica|October 1, 1977
The pharmacology of a new potent, long acting neuroleptic, piflutixolI M Nielsen, V Boeck, A V Christensen, et al.
Clinical Neuropharmacology|January 1, 1992
Pharmacological profile of the atypical neuroleptic sertindoleJ Hyttel, J Arnt, B Costall, et al.
Pageof 10